Evaxion announces financing commitments totaling up to USD 20 million with Negma GroupGlobeNewsWire • 08/01/23
Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureusGlobeNewsWire • 07/31/23
Evaxion's AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trialGlobeNewsWire • 06/03/23
Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01GlobeNewsWire • 05/25/23
Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccinesGlobeNewsWire • 05/25/23
Evaxion announces promising clinical data for DNA-based personalized cancer immunotherapy EVX-02: Phase 1/2a trial met both primary and secondary endpointsGlobeNewsWire • 04/18/23
Evaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platformGlobeNewsWire • 04/13/23
Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to PatientsGlobeNewsWire • 03/28/23
Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patientsGlobeNewsWire • 03/23/23
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)GlobeNewsWire • 03/14/23
Evaxion receives FDA fast-track designation for personalized cancer immunotherapyGlobeNewsWire • 01/19/23
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01GlobeNewsWire • 01/03/23
Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023GlobeNewsWire • 12/15/22
Evaxion and ExpreS²ion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidateGlobeNewsWire • 12/06/22
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02GlobeNewsWire • 11/17/22